SCHEMBL2270281

SCHEMBL2270281

O=C(Nc1cc(Oc2ccc(Cl)cc2Cl)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.62
PYGM P11217 5/20 0.61
PYGL P06737 4/20 0.61
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
PKM P14618 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
SERPINE1 P05121 3/20 0.59
MRGPRX4 Q96LA9 1/20 0.58
GRIK1 P39086 2/20 0.54
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 1/20 0.52
KCNH2 Q12809 1/20 0.52
PPARG P37231 1/20 0.52
PARP1 P09874 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145423 0.91 PYGM (0.61) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL2271528 0.89 PYGM (0.61) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL2272347 0.87 SERPINE1 (0.69) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL14428240 0.86 PNLIP (0.60) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL2270304 0.86 MEN1 (0.61) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL2270537 0.86 PNLIP (0.54) PNLIPPYGMPYGLMEN1KMT2A
SCHEMBL2274838 0.84 SERPINE1 (0.66) PYGMPYGLMEN1KMT2APKM
SCHEMBL2268139 0.84 PYGM (0.61) PYGMPYGLMEN1KMT2APKM
SCHEMBL2269138 0.83 SERPINE1 (0.57) PYGMPYGLMEN1KMT2APKM
SCHEMBL2273110 0.83 SERPINE1 (0.60) PYGMPYGLMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PNLIP 4862/4885PYGM 1299/4885PYGL 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.